CHIEF HF Trial was recently presented at the AHA 2021 meeting. It tested an #SGLT2Inhibitor #CANAGLIFLOZIN in #HEARTFAILURE. CHIEF HF Trial or CANAGLIFLOZIN in HEART FAILURE which was recently presented at AHA 2021 is yet to be published. If you were searching about CHIEF HF Trial or role of CANAGLIFLOZIN in HEART FAILURE you can find it in this video. The authors first presented its results in AHA 2021.